A North Carolina woman who took Taxotere has filed suit against the makers of cancer drug Taxotere, alleging that it caused her disfiguring permanent alopecia.
The case is Kathy Mottola v. Sanofi S.A., Aventis Pharma S.A., and Sanofi-Aventis U.S. LLC, Case 3:16-cv-00255-RJC-DCK. The emerging litigation is ripe for a motion to consolidate them into a federal multi-district litigation docket, because complaints involving Taxotere (Docetaxel) have been filed in multiple jurisdictions, including US District Courts in Illinois, North Carolina, Florida, Mississippi, Kansas, Louisiana and Colorado.
- Defendant Sanofi S.A. is a corporation or Société Anonyme organized and existing under the laws of France, having its principal place of business in Paris, France.
- Defendant Aventis Pharma S.A. is a corporation or Société Anonyme organized and existing under the laws of France, having its principal place of business in Antony, France.
- Defendant Sanofi-Aventis U.S. LLC is a Delaware limited liability company, which has its principal place of business at 55 Corporate Drive, Bridgewater, New Jersey.
Taxotere is a drug used to treat various forms of cancer, including but not limited to breast cancer. It is a part of a family of drugs commonly referred to as Taxanes.
On January 4th, 2013, Plaintiff Kathy Mottola underwent a right breast partial needle mastectomy performed by Richard White at Carolinas Medical Center in Charlotte, North Carolina. A biopsy had demonstrated invasive mammary carcinoma in her right breast. Following the mastectomy, she met with her oncologist to discuss further treatment.
Neither Mottola nor her treating healthcare providers were aware of or informed by Defendants that disfiguring permanent alopecia can occur following treatment with Taxotere. Accordingly, she underwent chemotherapy that included Taxotere. Following the completion of chemotherapy on May 23, 2013, she suffered from disfiguring permanent alopecia.
Despite the fact that Defendants disclosed risks associated with Taxotere and permanent alopecia to patients and regulatory agencies in other countries, they failed to either alert Plaintiff, the public, and the scientific community in the US or to perform further investigation into the safety of Taxotere. Defendants failed to update the warnings forthe drug, and failed to disclose the results of additional studies as Defendants learned new facts regarding the defects and risks of their product.
Thousands of women were exposed to the risk of disfiguring permanent alopecia without any warning and without any additional benefit.